2196 Stock Overview
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.00 |
| 52 Week High | CN¥19.50 |
| 52 Week Low | CN¥11.32 |
| Beta | 0.72 |
| 11 Month Change | -4.37% |
| 3 Month Change | 12.72% |
| 1 Year Change | -21.52% |
| 33 Year Change | -65.00% |
| 5 Year Change | -36.51% |
| Change since IPO | -47.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2196 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.2% | 0.1% | -2.1% |
| 1Y | -21.5% | -9.5% | 9.7% |
Return vs Industry: 2196 underperformed the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 2196 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 2196 volatility | |
|---|---|
| 2196 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2196 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2196's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 39,309 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 2196 fundamental statistics | |
|---|---|
| Market cap | HK$67.42b |
| Earnings (TTM) | HK$2.27b |
| Revenue (TTM) | HK$44.70b |
33.1x
P/E Ratio1.7x
P/S RatioIs 2196 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2196 income statement (TTM) | |
|---|---|
| Revenue | CN¥41.61b |
| Cost of Revenue | CN¥21.83b |
| Gross Profit | CN¥19.78b |
| Other Expenses | CN¥17.67b |
| Earnings | CN¥2.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 47.55% |
| Net Profit Margin | 5.08% |
| Debt/Equity Ratio | 55.0% |
How did 2196 perform over the long term?
See historical performance and comparison